Alzamend Neuro, Inc. SEC filings ALZN
Alzamend Neuro, Inc. has 397 filings in SEC EDGAR's recent list, going back to Jun 22, 2016. Its latest annual report, Form 10-K, was filed on Jul 22, 2026 for the period ended Apr 30, 2026. The latest quarterly report (Form 10-Q) was filed on Sep 10, 2026, covering the quarter ended Jul 31, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (regulation fd disclosure). The company's fiscal year ends on April 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K | Annual report | Jul 22, 2026 | Apr 30, 2026 |
| 10-K | Annual report | Jul 22, 2025 | Apr 30, 2025 |
| 10-K | Annual report | Jul 30, 2024 | Apr 30, 2024 |
| 10-K | Annual report | Jul 27, 2023 | Apr 30, 2023 |
| 10-K | Annual report | Jul 19, 2022 | Apr 30, 2022 |
| 10-K | Annual report | Jul 29, 2021 | Apr 30, 2021 |
Showing 6 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALZN (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- DE
- Headquarters
- Atlanta, GA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1677077
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.